2′,3′-Di-O-acetyl-5′-deoxy-5-fluorocytidine CAS 161599-46-8 Purity ≥99.0% Capecitabine Intermediate Factory

Capecitabine (CAS: 154361-50-9) is a new form of oral fluorinated pyrimidine drug. Capecitabine was developed by Roche Pharmaceuticals, and its commercial name is Xeloda. Capecitabine can change in vivo into 5- FU, an anti-metabolizim fluorine pyrimidine deoxynucleoside carbamate drug that targets cancer cells to inhibit cell division and disrupt RNA and protein synthesis. Its effects are significantly tied to the level of TP enzyme expression in neoplastic tissue and to DPD enzyme in vivo expression. It is suitable as further treatment for advanced primary or metastatic breast cancer patients who have not responded to paclitaxel or anthracycline antibiotics. As an anticancer drug, it is mostly used to treat advanced primary or metastatic breast cancer, as well as in treatment for non-small cell lung cancer, pancreatic cancer, bladder cancer, rectal cancer, colon cancer, gastric cancer, and other solid tumors.